{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-09-01T19:43:08.210677+00:00","company":{"ticker":"ATXI","cik":1644963,"company_name":"AVENUE THERAPEUTICS, INC."},"pagination":{"limit":100,"returned":50,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Aegis Capital Corp.","detail":"underwriting","count":1,"first_seen":"2023-02-01T23:59:59+00:00","last_seen":"2023-02-01T23:59:59+00:00","evidence_fact_ids":[182699]},{"display_name":"AnnJi Pharmaceutical Co. Ltd.","detail":"license","count":1,"first_seen":"2023-03-02T23:59:59+00:00","last_seen":"2023-03-02T23:59:59+00:00","evidence_fact_ids":[174448]},{"display_name":"Duke University","detail":"license","count":1,"first_seen":"2026-02-23T23:59:59+00:00","last_seen":"2026-02-23T23:59:59+00:00","evidence_fact_ids":[31416]},{"display_name":"H.C. Wainwright & Co. LLC","detail":"atm_program","count":1,"first_seen":"2024-05-13T23:59:59+00:00","last_seen":"2024-05-13T23:59:59+00:00","evidence_fact_ids":[47191]},{"display_name":"each of the Company’s executive officers, directors and the holders of 10% or more of the Company’s outstanding shares of Common Stock","detail":"equity_purchase","count":1,"first_seen":"2023-02-01T23:59:59+00:00","last_seen":"2023-02-01T23:59:59+00:00","evidence_fact_ids":[182701]},{"display_name":"the same institutional accredited investor","detail":"equity_purchase","count":1,"first_seen":"2023-02-01T23:59:59+00:00","last_seen":"2023-02-01T23:59:59+00:00","evidence_fact_ids":[182698]}],"ma_counterparty":[{"display_name":"Fortress Biotech, Inc.","detail":"acquisition","count":1,"first_seen":"2022-11-08T23:59:59+00:00","last_seen":"2022-11-08T23:59:59+00:00","evidence_fact_ids":[198560]}]},"facts":[{"fact_type":"material_agreement","fact_key":"6a5b870d72ddaae79b95b9193bc4b173f4248c7f","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2026-02-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"License Agreement","agreement_type":"license","counterparty":"Duke University","effective_date":"2026-02-18","item_codes_triggered":["1.01"],"value_text":null},"claim":"AVENUE THERAPEUTICS, INC. entered into License Agreement with Duke University (effective 2026-02-18).","evidence_excerpt":"On February 18, 2026, Avenue Therapeutics, Inc. (the “Company”) entered into a license agreement (the “License Agreement”) with Duke University (“Duke”), whereby the Company obtained from Duke an exclusive, worldwide license to certain patents and know-how","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-018582","anchor_url":"https://secwatch.observer/filing/0001104659-26-018582#claim-6a5b870d72ddaae79b95b9193bc4b173f4248c7f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465926018582/0001104659-26-018582-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"2a4fc1f46bb5dc330e5f45c4a61032e874da6515","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2025-03-17T23:59:59+00:00","payload":{"company_response":"hearing_requested","compliance_status":"delisting_pending","cure_deadline":"2025-03-14","deficiency_type":"stockholders_equity","delisting_effective_date":"2025-03-19","exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$2,500,000","notice_date":"2025-03-17","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(b)(1)","reported_value":null,"rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"March 17, 2025, The Nasdaq Stock Market LLC\n(“Nasdaq”) notified Avenue Therapeutics, Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”)\nhas determined to delist the Company’s common stock and that trading of the Company’s common stock will be suspended at the\nopen of trading on March 19, 2025. As previously reported, the Company was in violation\nof Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity\nof at least $2,500,000. Also as previously reported, on November 26, 2024, the Company received a delist let","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-024505","anchor_url":"https://secwatch.observer/filing/0001104659-25-024505#claim-2a4fc1f46bb5dc330e5f45c4a61032e874da6515","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465925024505/0001104659-25-024505-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"3c039240c3c54e00cb0be293c312c6b9ba5d08c8","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-11-29T23:59:59+00:00","payload":{"company_response":"The Company intends to timely request a hearing before the Panel.","compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"$2,500,000","notice_date":"2024-11-26","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(b)(1)","reported_value":"$1,652,000","rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"least $2,500,000 (the “Stockholders’ Equity\nRequirement”). The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2024 reported stockholders’\nequity of $1,652,000. In a decision dated June 3, 2024, a Nasdaq Hearings\nPanel (the “Panel”) previously had confirmed that the Company regained compliance with the Stockholders’ Equity","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-124081","anchor_url":"https://secwatch.observer/filing/0001104659-24-124081#claim-3c039240c3c54e00cb0be293c312c6b9ba5d08c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924124081/0001104659-24-124081-index.htm"},{"fact_type":"earnings_release","fact_key":"12d9b2e7eb51223df495bfb187da73c695e983e9","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":"$15.40 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$4.3 million, or $15.40 per share","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":null},"claim":"AVENUE THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: net income $4.3 million, or $15.40 per share, EPS $15.40 per share.","evidence_excerpt":"Net loss attributable to common stockholders for the first quarter of 2024 was $4.3 million, or $15.40 per share, compared to a net loss of $7.5 million, or $101.57 per share, for the first quarter of 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-016818","anchor_url":"https://secwatch.observer/filing/0001437749-24-016818#claim-12d9b2e7eb51223df495bfb187da73c695e983e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924016818/0001437749-24-016818-index.htm"},{"fact_type":"material_agreement","fact_key":"793fb5da6d1aed2030450954ac76e3e7a35b4c90","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"At the Market Offering Agreement","agreement_type":"atm_program","counterparty":"H.C. Wainwright & Co. LLC","effective_date":"2024-05-10","item_codes_triggered":["1.01"],"value_text":"$3,850,000"},"claim":"AVENUE THERAPEUTICS, INC. entered into At the Market Offering Agreement with H.C. Wainwright & Co. LLC valued at $3,850,000 (effective 2024-05-10).","evidence_excerpt":"On May 10, 2024, Avenue Therapeutics, Inc. (the “ Company ”) entered into an At the Market Offering Agreement (the “ Offering Agreement ”) with H.C. Wainwright & Co. LLC (the “ Manager ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-016081","anchor_url":"https://secwatch.observer/filing/0001437749-24-016081#claim-793fb5da6d1aed2030450954ac76e3e7a35b4c90","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924016081/0001437749-24-016081-index.htm"},{"fact_type":"material_agreement","fact_key":"edbda14adccf2c26fc378d6c7a50eb3df11663f5","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-05-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Inducement Letters","agreement_type":"equity_purchase","counterparty":"certain investors (the October 2022 Investors, November 2023 Investors, and January 2024 Investors)","effective_date":"2024-04-28","item_codes_triggered":["1.01"],"value_text":"approximately $4.4 million"},"claim":"AVENUE THERAPEUTICS, INC. entered into Inducement Letters with certain investors (the October 2022 Investors, November 2023 Investors, and January 2024 Investors) valued at approximately $4.4 million (effective 2024-04-28).","evidence_excerpt":"On April 28, 2024, Avenue Therapeutics, Inc. (the “ Company ”) entered into inducement offer letter agreements (the “ Inducement Letters ”) with (i) certain investors (the “ October 2022 Investors ”) that hold certain outstanding warrants to purchase up to an aggregate of 27,271 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), originally issued to the October 2022 Investors on October 11, 2022 (the “ October 2022 Warrants ”); (ii)  certain investors (the “ November 2023 Investors ”) that hold certain outstanding Series A and Series B warrants to purchase up to an aggregate of 221,333 shares of Common Stock, originally issued to the November 2023 Investors on October 31, 2023 (the “ November 2023 Warrants ”); and (iii) certain investors (the “ January 2024 Investors ” and, collectively with the October 2022 Investors and November 2023 Investors, the “ Holders ”) that hold certain outstanding Series A and Series B warrants to purchase up to an agg","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-014178","anchor_url":"https://secwatch.observer/filing/0001437749-24-014178#claim-edbda14adccf2c26fc378d6c7a50eb3df11663f5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924014178/0001437749-24-014178-index.htm"},{"fact_type":"governance_change","fact_key":"c397a18f53d78f1f440e5f59c2ade38d759eae91","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-04-26T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-04-26","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Amendment to effect a 1-for-75 reverse stock split of common stock"},"claim":"AVENUE THERAPEUTICS, INC.: Filed Certificate of Amendment to effect a 1-for-75 reverse stock split of common stock (effective 2024-04-26).","evidence_excerpt":"On April 25, 2024, Avenue Therapeutics, Inc. (the “ Company ”) filed a Certificate of Amendment to its Third Amended and Restated Certificate of Incorporation (the “ Amendment ”) with the Secretary of State of the State of Delaware to effect a 1-for-75 reverse stock split","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-013436","anchor_url":"https://secwatch.observer/filing/0001437749-24-013436#claim-c397a18f53d78f1f440e5f59c2ade38d759eae91","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924013436/0001437749-24-013436-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"aa703d2d6ba5d9c5997c967fff19d97be44c31e2","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-03-29T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"hearing_requested","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-03-26","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)","5550(b)(2)"],"rules_cited_in_text":true},"claim":"AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5550(b)(2)).","evidence_excerpt":"March 26, 2024, the Staff issued a delist determination with respect to the deficiency, as required by the Nasdaq Listing Rules. Notwithstanding, and as previously disclosed, on February 15, 2024, the Company attended a hearing before the Nasdaq Hearings Panel (the “Panel”), at which the Company presented its plan to evidence compliance with both the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “Equity Rule”) as well as the Bid Price Rule (together with the Bid Price Rule, the “Rules”). By decision dated March 11, 2024, the Panel granted the Company","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-010044","anchor_url":"https://secwatch.observer/filing/0001437749-24-010044#claim-aa703d2d6ba5d9c5997c967fff19d97be44c31e2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924010044/0001437749-24-010044-index.htm"},{"fact_type":"earnings_release","fact_key":"56f3d16f1a30077d06b7b7b8c350b3c942dcead0","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-03-18T23:59:59+00:00","payload":{"eps_text":"$0.98 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63","period_text":"the fiscal year ended December 31, 2023","report_date":"2024-03-18","result_type":"reported_results","revenue_text":null},"claim":"AVENUE THERAPEUTICS, INC. reported the fiscal year ended December 31, 2023 results: net income Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63, EPS $0.98 per share.","evidence_excerpt":"Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63 per share, in 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-035544","anchor_url":"https://secwatch.observer/filing/0001104659-24-035544#claim-56f3d16f1a30077d06b7b7b8c350b3c942dcead0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924035544/0001104659-24-035544-index.htm"},{"fact_type":"shareholder_vote","fact_key":"67d881cf1ccd55421c34ed2279796e9e33eb6604","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-03-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-06","outcome":"passed","proposal_text":"Reverse stock split within a range of between 30-for-1 and 75-for-1","proposal_type":"reverse_split","results":[]},"claim":"AVENUE THERAPEUTICS, INC. shareholders approved Reverse stock split within a range of between 30-for-1 and 75-for-1 at the 2024-03-06 meeting.","evidence_excerpt":"Effective March 6, 2024, the holders of a majority of the voting power of the capital stock of Avenue Therapeutics, Inc. (the “ Company ”) executed a written consent approving a grant of discretionary authority to the board of directors of the Company (the “ Board ”) to, without further stockholder approval, effect a reverse stock split of the Company’s issued and outstanding common stock within a range of between 30-for-1 and 75-for-1 (with the Board being authorized to determinate the exact ratio) (the “ Reverse Stock Split ”) by filing an amendment (the “ Amendment ”) to the Company’s Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-032401","anchor_url":"https://secwatch.observer/filing/0001104659-24-032401#claim-67d881cf1ccd55421c34ed2279796e9e33eb6604","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924032401/0001104659-24-032401-index.htm"},{"fact_type":"governance_change","fact_key":"6c0f72805bb3c110c17994455f2b0dc2c4b04e5b","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-02-23T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-02-20","item_codes_triggered":["5.03"],"summary_text":"Increased authorized common stock from 75,000,000 to 200,000,000 shares"},"claim":"AVENUE THERAPEUTICS, INC.: Increased authorized common stock from 75,000,000 to 200,000,000 shares (effective 2024-02-20).","evidence_excerpt":"On February 20, 2024, the Company filed a Certificate of Amendment to its Certificate of Incorporation (the “ Certificate of Amendment ”) with the Secretary of State for the State of Delaware effectuating the Authorized Shares Increase.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-027037","anchor_url":"https://secwatch.observer/filing/0001104659-24-027037#claim-6c0f72805bb3c110c17994455f2b0dc2c4b04e5b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924027037/0001104659-24-027037-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7a1856acbb4c5728f044510fb7deb36d9171761b","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-01-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-09","outcome":"passed","proposal_text":"Authorization of the issuance of shares of Common Stock underlying warrants in an amount equal to or in excess of 20% of outstanding Common Stock","proposal_type":"other","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"0","votes_against":"0","votes_for":"0","votes_withheld":"0"}]},"claim":"AVENUE THERAPEUTICS, INC. shareholders approved Authorization of the issuance of shares of Common Stock underlying warrants in an amount equal to or in excess of 20% of outstanding Common Stock at the 2024-01-09 meeting.","evidence_excerpt":"Effective January 9, 2024, the holders of a majority of the voting power of the capital stock of Avenue Therapeutics, Inc. (the “ Company ”) executed a written consent (i) approving an increase in the number of the Company’s authorized shares of common stock, par value $0.0001 per share (“ Common Stock ”), from 75,000,000 to 200,000,000 (the “ Authorized Share Increase ”) through the filing of an amendment (the “ Amendment ”) to the Company’s Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware and (ii) authorizing, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying warrants issued by the Company pursuant to those previously disclosed inducement letter agreements, dated as of January 5, 2024, by and between the Company and the investors named on the signature pages thereto, in an amount equal to or in excess of 20% of the number of shares of Common Stock outstanding immedi","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-003470","anchor_url":"https://secwatch.observer/filing/0001104659-24-003470#claim-7a1856acbb4c5728f044510fb7deb36d9171761b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924003470/0001104659-24-003470-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d8cd14efc33488a3a744fe2934137dab5f94d719","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-01-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-01-09","outcome":"passed","proposal_text":"Approval of an increase in the number of authorized shares of Common Stock from 75,000,000 to 200,000,000","proposal_type":"charter_amendment","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"0","votes_against":"0","votes_for":"0","votes_withheld":"0"}]},"claim":"AVENUE THERAPEUTICS, INC. shareholders approved Approval of an increase in the number of authorized shares of Common Stock from 75,000,000 to 200,000,000 at the 2024-01-09 meeting.","evidence_excerpt":"Effective January 9, 2024, the holders of a majority of the voting power of the capital stock of Avenue Therapeutics, Inc. (the “ Company ”) executed a written consent (i) approving an increase in the number of the Company’s authorized shares of common stock, par value $0.0001 per share (“ Common Stock ”), from 75,000,000 to 200,000,000 (the “ Authorized Share Increase ”) through the filing of an amendment (the “ Amendment ”) to the Company’s Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware and (ii) authorizing, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying warrants issued by the Company pursuant to those previously disclosed inducement letter agreements, dated as of January 5, 2024, by and between the Company and the investors named on the signature pages thereto, in an amount equal to or in excess of 20% of the number of shares of Common Stock outstanding immedi","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-003470","anchor_url":"https://secwatch.observer/filing/0001104659-24-003470#claim-d8cd14efc33488a3a744fe2934137dab5f94d719","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924003470/0001104659-24-003470-index.htm"},{"fact_type":"material_agreement","fact_key":"5f0e09fd26115bb6f356fef1598cbe8d450d61c8","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-01-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Inducement Letters","agreement_type":"equity_purchase","counterparty":"certain investors (the Holders)","effective_date":"2025-01-05","item_codes_triggered":["1.01"],"value_text":"aggregate gross proceeds of approximately $5.0 million"},"claim":"AVENUE THERAPEUTICS, INC. entered into Inducement Letters with certain investors (the Holders) valued at aggregate gross proceeds of approximately $5.0 million (effective 2025-01-05).","evidence_excerpt":"On January 5, 2024, Avenue Therapeutics, Inc. (the “Company ”) entered into (i) an inducement offer letter agreement (the “ January 2023 Investor Inducement Letter ”) with a certain investor (the “ January 2023 Investor ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-002318","anchor_url":"https://secwatch.observer/filing/0001104659-24-002318#claim-5f0e09fd26115bb6f356fef1598cbe8d450d61c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924002318/0001104659-24-002318-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"5575e81b02c8110670f1f05476d11fe11dea7178","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-11-24T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-11-20","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"November 20, 2023, the Staff formally\nnotified the Company that it had determined to delist the Company’s securities from Nasdaq based upon the Company’s continued\nnon-compliance with the Rule unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “ Panel ”).\nThe Company intends to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least pending\ncompletion of the hearing and the expiration of any extension that may be granted by the Panel to the Company. The Company is considering all options available\nto it to regain","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-120977","anchor_url":"https://secwatch.observer/filing/0001104659-23-120977#claim-5575e81b02c8110670f1f05476d11fe11dea7178","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923120977/0001104659-23-120977-index.htm"},{"fact_type":"earnings_release","fact_key":"78c05706e789a34e29b5c06872b680f499e79cbf","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"eps_text":"$0.06 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net income attributable to common stockholders for the third quarter of 2023 was $0.5 million, or $0.06 per share","period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-13","result_type":"reported_results","revenue_text":null},"claim":"AVENUE THERAPEUTICS, INC. reported the third quarter ended September 30, 2023 results: net income Net income attributable to common stockholders for the third quarter of 2023 was $0.5 million, or $0.06 per share, EPS $0.06 per share.","evidence_excerpt":"On November 13, 2023, Avenue Therapeutics, Inc. (the “Company” or “Avenue”) issued a press release to provide a corporate update and to announce its financial results for the three months ended September 30, 2023.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-23-031615","anchor_url":"https://secwatch.observer/filing/0001437749-23-031615#claim-78c05706e789a34e29b5c06872b680f499e79cbf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000143774923031615/0001437749-23-031615-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"8461efb65de0bc1aab03dd4790f174e0a8638af8","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-09-28T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2024-03-25","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2023-09-27","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2) (the “Minimum-Bid Price Requirement”)","reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"AVENUE THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"September 27, 2023, Avenue\nTherapeutics, Inc. (the “ Company ”) received a letter from the Staff of the Listing Qualifications Department (the “ Staff ”)\nof The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the bid price of the Company’s common stock (“ Common\nStock ”) had closed below $1.00 per share for 30 consecutive business days, and that, therefore, the Company was not in\ncompliance with Nasdaq Listing Rule 5550(a)(2) (the “ Minimum-Bid Price Requirement ”), which sets forth the minimum\nbid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq’s\nnotice has no i","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-104769","anchor_url":"https://secwatch.observer/filing/0001104659-23-104769#claim-8461efb65de0bc1aab03dd4790f174e0a8638af8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923104769/0001104659-23-104769-index.htm"},{"fact_type":"earnings_release","fact_key":"5aa139d0377c1241af1716dd618850d2591293cb","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"eps_text":"$0.52 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss attributable to common stockholders for the second quarter of 2023 was $4.0 million, or $0.52 per share","period_text":"second quarter ended June 30, 2023","report_date":"2023-08-10","result_type":"reported_results","revenue_text":null},"claim":"AVENUE THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: net income Net loss attributable to common stockholders for the second quarter of 2023 was $4.0 million, or $0.52 per share, EPS $0.52 per share.","evidence_excerpt":"On August 10, 2023, Avenue Therapeutics, Inc. (the “Company” or “Avenue”) issued a press release to provide a corporate update and to announce its financial results for the three months ended June 30, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-23-023068","anchor_url":"https://secwatch.observer/filing/0001437749-23-023068#claim-5aa139d0377c1241af1716dd618850d2591293cb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000143774923023068/0001437749-23-023068-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ab1b075ac6ccf3fca58a1550cacced6acf3a1ecc","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-06-26T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-22","outcome":"passed","proposal_text":"Non-binding advisory vote to approve compensation of named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"1,374,581","subject":null,"votes_abstain":"32,597","votes_against":"128,472","votes_for":"9,541,965","votes_withheld":null}]},"claim":"AVENUE THERAPEUTICS, INC. shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-22 meeting.","evidence_excerpt":"The vote, on a non-binding advisory basis, to approve the compensation of the Company’s named executive officers was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 9,541,965 128,472 32,597 1,374,581","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-074745","anchor_url":"https://secwatch.observer/filing/0001104659-23-074745#claim-ab1b075ac6ccf3fca58a1550cacced6acf3a1ecc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923074745/0001104659-23-074745-index.htm"},{"fact_type":"shareholder_vote","fact_key":"be65c0fbd2a9a6f40a7bbcd31e9c85fb70a42066","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-06-26T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-22","outcome":"passed","proposal_text":"Ratify the selection of KPMG LLP as independent registered accounting firm for the year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"8,204","votes_against":"245,962","votes_for":"10,823,449","votes_withheld":null}]},"claim":"AVENUE THERAPEUTICS, INC. shareholders approved Ratify the selection of KPMG LLP as independent registered accounting firm for the year ending December 31, 2023 at the 2023-06-22 meeting.","evidence_excerpt":"The vote on the proposal to ratify the selection of KPMG LLP as Avenue’s independent registered accounting firm for the year ending December 31, 2023 was as follows: Total Votes For Total Votes Against Abstentions 10,823,449 245,962 8,204","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-074745","anchor_url":"https://secwatch.observer/filing/0001104659-23-074745#claim-be65c0fbd2a9a6f40a7bbcd31e9c85fb70a42066","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923074745/0001104659-23-074745-index.htm"},{"fact_type":"shareholder_vote","fact_key":"45d3eae98221aaad20c12448e044ae1c6206b402","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-06-26T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-22","outcome":"passed","proposal_text":"Election of six directors to hold office until the 2024 annual meeting of stockholders","proposal_type":"director_election","results":[{"broker_non_votes":"1,374,581","subject":"Jay Kranzler, M.D., Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"9,598,212","votes_withheld":"104,822"},{"broker_non_votes":"1,374,581","subject":"Faith Charles","votes_abstain":null,"votes_against":null,"votes_for":"9,603,663","votes_withheld":"99,371"},{"broker_non_votes":"1,374,581","subject":"Neil Herskowitz","votes_abstain":null,"votes_against":null,"votes_for":"9,602,391","votes_withheld":"100,643"},{"broker_non_votes":"1,374,581","subject":"Alexandra MacLean, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"9,598,851","votes_withheld":"104,183"},{"broker_non_votes":"1,374,581","subject":"Curtis Oltmans","votes_abstain":null,"votes_against":null,"votes_for":"9,603,075","votes_withheld":"99,959"},{"broker_non_votes":"1,374,581","subject":"Lindsay A. Rosenwald, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"9,544,216","votes_withheld":"158,818"}]},"claim":"AVENUE THERAPEUTICS, INC. shareholders approved Election of six directors to hold office until the 2024 annual meeting of stockholders at the 2023-06-22 meeting.","evidence_excerpt":"The votes with respect to the election of six directors to hold office until the 2024 annual meeting of stockholders were as follows: Director Votes For Votes Withheld Broker Non-Votes Jay Kranzler, M.D., Ph.D. 9,598,212 104,822 1,374,581 Faith Charles 9,603,663 99,371 1,374,581 Neil Herskowitz 9,602,391 100,643 1,374,581 Alexandra MacLean, M.D. 9,598,851 104,183 1,374,581 Curtis Oltmans 9,603,075 99,959 1,374,581 Lindsay A. Rosenwald, M.D. 9,544,216 158,818 1,374,581","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-074745","anchor_url":"https://secwatch.observer/filing/0001104659-23-074745#claim-45d3eae98221aaad20c12448e044ae1c6206b402","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923074745/0001104659-23-074745-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"fb1ed430a92181b453afe2b663c3a729ff9e2ede","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-05-22T23:59:59+00:00","payload":{"company_response":"The Company intends to submit a Compliance Plan on or before July 3, 2023.","compliance_status":"plan_due","cure_deadline":"2023-07-03","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$2,500,000","notice_date":"2023-05-19","notice_type":"deficiency_notice","plan_due_date":"2023-07-03","raw_rule_text":"Nasdaq Listing Rule 5550(b)(1)","reported_value":"negative $2,157,000","rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"AVENUE THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"$2,500,000 (the “Stockholders’ Equity\nRequirement”). The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, reported\nstockholders’ equity of negative $2,157,000. The Letter further noted that as of the letter date, the Company did not have a\nmarket value of listed securities of $35 million, or net income from continued operations of","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-063143","anchor_url":"https://secwatch.observer/filing/0001104659-23-063143#claim-fb1ed430a92181b453afe2b663c3a729ff9e2ede","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923063143/0001104659-23-063143-index.htm"},{"fact_type":"earnings_release","fact_key":"59592784558e8600964cd061ed7c1ff992400147","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-05-12T23:59:59+00:00","payload":{"eps_text":"$1.37 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$7.5 million, or $1.37 per share","period_text":"the first quarter ended March 31, 2023","report_date":"2023-05-12","result_type":"reported_results","revenue_text":null},"claim":"AVENUE THERAPEUTICS, INC. reported the first quarter ended March 31, 2023 results: net income $7.5 million, or $1.37 per share, EPS $1.37 per share.","evidence_excerpt":"Net loss attributable to common stockholders for the first quarter of 2023 was $7.5 million, or $1.37 per share, compared to a net loss of $2.9 million, or $2.05 per share, for the first quarter of 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-059454","anchor_url":"https://secwatch.observer/filing/0001104659-23-059454#claim-59592784558e8600964cd061ed7c1ff992400147","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923059454/0001104659-23-059454-index.htm"},{"fact_type":"earnings_release","fact_key":"53ebeaaf8ef4dca81c877715a33e147378001762","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"eps_text":"$1.63 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss attributable to common stockholders for the full year 2022 was $3.6 million, or $1.63 per share","period_text":"the full year ended December 31, 2022","report_date":"2023-03-30","result_type":"reported_results","revenue_text":null},"claim":"AVENUE THERAPEUTICS, INC. reported the full year ended December 31, 2022 results: net income Net loss attributable to common stockholders for the full year 2022 was $3.6 million, or $1.63 per share, EPS $1.63 per share.","evidence_excerpt":"Avenue Therapeutics, Inc. issued a press release to provide a corporate update and to announce its financial results for the three months and full year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-039135","anchor_url":"https://secwatch.observer/filing/0001104659-23-039135#claim-53ebeaaf8ef4dca81c877715a33e147378001762","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923039135/0001104659-23-039135-index.htm"},{"fact_type":"executive_change","fact_key":"68b21b7f34","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-03-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-07","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Jay Kranzler was appointed as Chairman of the Board at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"appointed Jay Kranzler, M.D., Ph.D. to serve as Chairman of the Board, effective immediately","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-030103","anchor_url":"https://secwatch.observer/filing/0001104659-23-030103#claim-68b21b7f34","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/0001104659-23-030103-index.htm"},{"fact_type":"executive_change","fact_key":"aff3c771d5","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-03-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-07","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Alexandra MacLean was appointed as Director at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"appointed Alexandra MacLean, M.D., Chief Executive Officer of the Company, to the Board as a director, effective immediately","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-030103","anchor_url":"https://secwatch.observer/filing/0001104659-23-030103#claim-aff3c771d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/0001104659-23-030103-index.htm"},{"fact_type":"material_agreement","fact_key":"65d88a95a84c7960524c58d43da9175a24892a5e","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-03-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"License Agreement","agreement_type":"license","counterparty":"AnnJi Pharmaceutical Co. Ltd.","effective_date":"2023-02-28","item_codes_triggered":["1.01"],"value_text":"Initial cash license fee of $3.0 million ($2.0 million within 60 days, $1.0 million within 180 days)"},"claim":"AVENUE THERAPEUTICS, INC. entered into License Agreement with AnnJi Pharmaceutical Co. Ltd. valued at Initial cash license fee of $3.0 million ($2.0 million within 60 days, $1.0 million within 180 days) (effective 2023-02-28).","evidence_excerpt":"On February 28, 2023, Avenue Therapeutics, Inc. (the “ Company ”) entered into a license agreement with AnnJi Pharmaceutical Co. Ltd., a Taiwanese company (“ AnnJi ”), whereby the Company obtained an exclusive license (the “ License Agreement ”) from AnnJi to intellectual property rights pertaining to the molecule known as JM17, which activates Nrf1 and Nrf2, enhances androgen receptor degradation and underlies AJ201, a clinical product candidate currently in a Phase 1b/2a clinical trial in the U.S. for the treatment of spinal and bulbar muscular atrophy (“ SBMA ”), also known as Kennedy’s Disease. Under the License Agreement, in exchange for exclusive (as described below) rights to the intellectual property underlying the AJ201 product candidate, the Company will pay an initial cash license fee of $3.0 million, of which $2.0 million is payable within 60 days and $1 million payable within 180 days after the effective date of the License Agreement. The Company is also obligated to issue","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-027680","anchor_url":"https://secwatch.observer/filing/0001104659-23-027680#claim-65d88a95a84c7960524c58d43da9175a24892a5e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923027680/0001104659-23-027680-index.htm"},{"fact_type":"governance_change","fact_key":"064cd310cc40518ced69b0d63b5125a59a0f1f03","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-02-10T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-02-09","item_codes_triggered":["5.03"],"summary_text":"Removed special rights provisions for InvaGen Pharmaceuticals and changed stockholder meeting quorum requirement to majority of outstanding voting power."},"claim":"AVENUE THERAPEUTICS, INC.: Removed special rights provisions for InvaGen Pharmaceuticals and changed stockholder meeting quorum requirement to majority of outstanding voting power (effective 2023-02-09).","evidence_excerpt":"On February 9, 2023, the Board of Directors (the “Board”) of Avenue Therapeutics, Inc. (the “Company”) adopted the Second Amended and Restated Bylaws of the Company (the “Amended Bylaws”), effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-018503","anchor_url":"https://secwatch.observer/filing/0001104659-23-018503#claim-064cd310cc40518ced69b0d63b5125a59a0f1f03","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923018503/0001104659-23-018503-index.htm"},{"fact_type":"governance_change","fact_key":"4674a1312b0e7972734a0901a60d0145da688a5c","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-02-03T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-02-02","item_codes_triggered":["5.03"],"summary_text":"Increased authorized shares of common stock from 20,000,000 to 75,000,000, adding 55,000,000 shares."},"claim":"AVENUE THERAPEUTICS, INC.: Increased authorized shares of common stock from 20,000,000 to 75,000,000, adding 55,000,000 shares (effective 2023-02-02).","evidence_excerpt":"On February 2, 2023, following the 2022 Annual Meeting, the Company filed a certificate of amendment giving effect to the Authorized Shares Amendment with the Secretary of State of the State of Delaware.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-010476","anchor_url":"https://secwatch.observer/filing/0001104659-23-010476#claim-4674a1312b0e7972734a0901a60d0145da688a5c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923010476/0001104659-23-010476-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a5d43daea39d0bd267b55a009373eb01665695bf","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-02-03T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-01-30","outcome":"passed","proposal_text":"Approval of an amendment to the Incentive Plan to increase the number of shares of Common Stock available for issuance from 266,666 to 5,266,666","proposal_type":"equity_plan","results":[{"broker_non_votes":"956,265","subject":null,"votes_abstain":"39,271","votes_against":"415,582","votes_for":"6,128,908","votes_withheld":null}]},"claim":"AVENUE THERAPEUTICS, INC. shareholders approved Approval of an amendment to the Incentive Plan to increase the number of shares of Common Stock available for issuance from 266,666 to 5,266,666 at the 2023-01-30 meeting.","evidence_excerpt":"The vote with respect to the approval of an amendment to the Plan to increase the number of shares of Common Stock authorized for issuance thereunder by 5,000,000 shares from 266,666 shares to 5,266,666 shares available for issuance under the Plan was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 6,128,908 415,582 39,271 956,265","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-23-010476","anchor_url":"https://secwatch.observer/filing/0001104659-23-010476#claim-a5d43daea39d0bd267b55a009373eb01665695bf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923010476/0001104659-23-010476-index.htm"},{"fact_type":"shareholder_vote","fact_key":"318d4edfa8b7c924481eabbe540d3f34ee6931a9","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-02-03T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-01-30","outcome":"passed","proposal_text":"Approval of an amendment to the Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock by 55,000,000 shares from 20,000,000 to 75,000,000","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"25,583","votes_against":"481,173","votes_for":"7,033,270","votes_withheld":null}]},"claim":"AVENUE THERAPEUTICS, INC. shareholders approved Approval of an amendment to the Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock by 55,000,000 shares from 20,000,000 to 75,000,000 at the 2023-01-30 meeting.","evidence_excerpt":"The vote with respect to the approval of an amendment to Avenue’s Third Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of Common Stock by 55,000,000 shares from 20,000,000 shares to 75,000,000 was as follows: Total Votes For Total Votes Against Abstentions 7,033,270 481,173 25,583","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-23-010476","anchor_url":"https://secwatch.observer/filing/0001104659-23-010476#claim-318d4edfa8b7c924481eabbe540d3f34ee6931a9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923010476/0001104659-23-010476-index.htm"},{"fact_type":"shareholder_vote","fact_key":"92f26a9a1202fe4685e2b27c7ae60d6e4d1ea915","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-02-03T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-01-30","outcome":"passed","proposal_text":"Election of five directors to hold office until the 2023 annual meeting of stockholders","proposal_type":"director_election","results":[{"broker_non_votes":"956,265","subject":"Lindsay A. Rosenwald, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"6,428,601","votes_withheld":"155,160"},{"broker_non_votes":"956,265","subject":"Faith Charles","votes_abstain":null,"votes_against":null,"votes_for":"6,466,198","votes_withheld":"117,563"},{"broker_non_votes":"956,265","subject":"Neil Herskowitz","votes_abstain":null,"votes_against":null,"votes_for":"6,468,194","votes_withheld":"115,567"},{"broker_non_votes":"956,265","subject":"Jay Kranzler, M.D., Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"6,431,282","votes_withheld":"152,479"},{"broker_non_votes":"956,265","subject":"Curtis Oltmans","votes_abstain":null,"votes_against":null,"votes_for":"6,447,327","votes_withheld":"136,434"}]},"claim":"AVENUE THERAPEUTICS, INC. shareholders approved Election of five directors to hold office until the 2023 annual meeting of stockholders at the 2023-01-30 meeting.","evidence_excerpt":"The votes with respect to the election of five directors to hold office until the 2023 annual meeting of stockholders were as follows: Director Votes For Votes Withheld Broker Non-Votes Lindsay A. Rosenwald, M.D. 6,428,601 155,160 956,265 Faith Charles 6,466,198 117,563 956,265 Neil Herskowitz 6,468,194 115,567 956,265 Jay Kranzler, M.D., Ph.D. 6,431,282 152,479 956,265 Curtis Oltmans 6,447,327 136,434 956,265","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-23-010476","anchor_url":"https://secwatch.observer/filing/0001104659-23-010476#claim-92f26a9a1202fe4685e2b27c7ae60d6e4d1ea915","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923010476/0001104659-23-010476-index.htm"},{"fact_type":"material_agreement","fact_key":"ac8ad8944ace809fa402676148962693429d254d","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-02-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Lock-Up Agreement","agreement_type":"equity_purchase","counterparty":"each of the Company’s executive officers, directors and the holders of 10% or more of the Company’s outstanding shares of Common Stock","effective_date":"2023-01-27","item_codes_triggered":["1.01"],"value_text":null},"claim":"AVENUE THERAPEUTICS, INC. entered into Lock-Up Agreement with each of the Company’s executive officers, directors and the holders of 10% or more of the Company’s outstanding shares of Common Stock (effective 2023-01-27).","evidence_excerpt":"Each of the Company’s executive officers, directors and the holders of 10% or more of the Company’s outstanding shares of Common Stock entered into a lock-up agreement (the “ Lock-Up Agreement ”) pursuant to which they agreed not to sell or transfer any securities of the Company held by them for a period commencing on January 27, 2023 and ending ninety (90) days after the Effective Date (as defined in PIPE Purchase Agreement), subject to limited exceptions.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-008989","anchor_url":"https://secwatch.observer/filing/0001104659-23-008989#claim-ac8ad8944ace809fa402676148962693429d254d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm"},{"fact_type":"material_agreement","fact_key":"8b12e5e286cff73e24ac21990655e945ebbb53c0","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-02-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registration Rights Agreement","agreement_type":"equity_purchase","counterparty":"the investor","effective_date":"2023-01-27","item_codes_triggered":["1.01"],"value_text":null},"claim":"AVENUE THERAPEUTICS, INC. entered into Registration Rights Agreement with the investor (effective 2023-01-27).","evidence_excerpt":"In connection with the PIPE Purchase Agreement, the Company entered into a registration rights agreement (the “ Registration Rights Agreement ”) with the investor.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-008989","anchor_url":"https://secwatch.observer/filing/0001104659-23-008989#claim-8b12e5e286cff73e24ac21990655e945ebbb53c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm"},{"fact_type":"material_agreement","fact_key":"50d871736eedebaf133e319f16afe58ce2455b13","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-02-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Placement Agent Agreement","agreement_type":"underwriting","counterparty":"Aegis Capital Corp.","effective_date":"2023-01-27","item_codes_triggered":["1.01"],"value_text":null},"claim":"AVENUE THERAPEUTICS, INC. entered into Placement Agent Agreement with Aegis Capital Corp. (effective 2023-01-27).","evidence_excerpt":"Aegis Capital Corp. (“ Aegis ”) acted as the exclusive placement agent in connection with the Registered Offering and the Private Placement under a Placement Agent Agreement, dated as of January 27, 2023, between the Company and Aegis (the “ Placement Agent Agreement ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-008989","anchor_url":"https://secwatch.observer/filing/0001104659-23-008989#claim-50d871736eedebaf133e319f16afe58ce2455b13","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm"},{"fact_type":"material_agreement","fact_key":"9f5b01151ff4c52766cfcaf193c1facb9d3cf614","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-02-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"PIPE Purchase Agreement","agreement_type":"equity_purchase","counterparty":"the same institutional accredited investor","effective_date":"2023-01-27","item_codes_triggered":["1.01"],"value_text":"approximately $0.24 million"},"claim":"AVENUE THERAPEUTICS, INC. entered into PIPE Purchase Agreement with the same institutional accredited investor valued at approximately $0.24 million (effective 2023-01-27).","evidence_excerpt":"On January 27, 2023, the Company also entered into a Securities Purchase Agreement (the “ PIPE Purchase Agreement ”) with the same institutional accredited investor","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-008989","anchor_url":"https://secwatch.observer/filing/0001104659-23-008989#claim-9f5b01151ff4c52766cfcaf193c1facb9d3cf614","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm"},{"fact_type":"material_agreement","fact_key":"062b3610726cfd83bc8ee061a35ad365f04763cf","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-02-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registered Purchase Agreement","agreement_type":"equity_purchase","counterparty":"a single institutional accredited investor","effective_date":"2023-01-27","item_codes_triggered":["1.01"],"value_text":"approximately $3.0 million"},"claim":"AVENUE THERAPEUTICS, INC. entered into Registered Purchase Agreement with a single institutional accredited investor valued at approximately $3.0 million (effective 2023-01-27).","evidence_excerpt":"On January 27, 2023, Avenue Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Registered Purchase Agreement ”) with a single institutional accredited investor","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-008989","anchor_url":"https://secwatch.observer/filing/0001104659-23-008989#claim-062b3610726cfd83bc8ee061a35ad365f04763cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm"},{"fact_type":"auditor_change","fact_key":"6f447caf839b721e33249f2e8102ed6d6b0935a9","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-01-25T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"KPMG LLP","disagreement_text":null,"effective_date":"2023-01-23","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"AVENUE THERAPEUTICS, INC. engaged KPMG LLP as its auditor.","evidence_excerpt":"Effective as of January 23, 2023, the Audit Committee engaged KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-006536","anchor_url":"https://secwatch.observer/filing/0001104659-23-006536#claim-6f447caf839b721e33249f2e8102ed6d6b0935a9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923006536/0001104659-23-006536-index.htm"},{"fact_type":"auditor_change","fact_key":"0ec49b5b3d5dc9d6a73ecab26635a671f75da7f9","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-01-25T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"BDO USA, LLP","disagreement_text":null,"effective_date":"2023-01-21","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"KPMG LLP"},"claim":"AVENUE THERAPEUTICS, INC. dismissed BDO USA, LLP as its auditor.","evidence_excerpt":"On January 21, 2023, the Audit Committee (the “Audit Committee”) of the Board of Directors of Avenue Therapeutics, Inc. (the “Company”) dismissed BDO USA, LLP (“BDO”) as the Company’s independent registered public accounting firm, effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-006536","anchor_url":"https://secwatch.observer/filing/0001104659-23-006536#claim-0ec49b5b3d5dc9d6a73ecab26635a671f75da7f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923006536/0001104659-23-006536-index.htm"},{"fact_type":"earnings_release","fact_key":"b723f4ef1ec72557ecb6bab6ebd8a67b89373ca8","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-11-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss attributable to common stockholders for the third quarter of 2022 was $0.7 million, or $0.45 per share","period_text":"the third quarter ended September 30, 2022","report_date":"2022-11-10","result_type":"reported_results","revenue_text":null},"claim":"AVENUE THERAPEUTICS, INC. reported the third quarter ended September 30, 2022 results: net income Net loss attributable to common stockholders for the third quarter of 2022 was $0.7 million, or $0.45 per share.","evidence_excerpt":"Avenue Therapeutics, Inc. (the “Company” or “Avenue”) issued a press release to provide a corporate update and to announce its financial results for the three months ended September 30, 2022.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001104659-22-117179","anchor_url":"https://secwatch.observer/filing/0001104659-22-117179#claim-b723f4ef1ec72557ecb6bab6ebd8a67b89373ca8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922117179/0001104659-22-117179-index.htm"},{"fact_type":"ma_transaction","fact_key":"d7a88c18c890a7981320d53a1f0a8ab121d7a631","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2022-11-08","consideration_text":null,"counterparty":"Fortress Biotech, Inc.","effective_date":"2022-11-08","item_codes_triggered":["2.01"]},"claim":"AVENUE THERAPEUTICS, INC. completed an acquisition involving Fortress Biotech, Inc. (closed 2022-11-08).","evidence_excerpt":"On November 8, 2022, following the satisfaction of the closing conditions of the Contribution Agreement, the Company completed the acquisition of a majority of the outstanding shares (common and preferred) of Baergic from Fortress.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-115713","anchor_url":"https://secwatch.observer/filing/0001104659-22-115713#claim-d7a88c18c890a7981320d53a1f0a8ab121d7a631","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922115713/0001104659-22-115713-index.htm"},{"fact_type":"executive_change","fact_key":"2a8baf4036","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-11-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-10-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"E. Garrett Ingram resigned as Director at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"each of Jaideep Gogtay, M.D. and E. Garrett Ingram, the two non-independent members of the Board originally selected by InvaGen, resigned as members of the Board and all committees thereof, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-114916","anchor_url":"https://secwatch.observer/filing/0001104659-22-114916#claim-2a8baf4036","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922114916/0001104659-22-114916-index.htm"},{"fact_type":"executive_change","fact_key":"007ca222de","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-11-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-10-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jaideep Gogtay, M.D. resigned as Director at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"each of Jaideep Gogtay, M.D. and E. Garrett Ingram, the two non-independent members of the Board originally selected by InvaGen, resigned as members of the Board and all committees thereof, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-114916","anchor_url":"https://secwatch.observer/filing/0001104659-22-114916#claim-007ca222de","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922114916/0001104659-22-114916-index.htm"},{"fact_type":"executive_change","fact_key":"2998da2eae","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-08-03T23:59:59+00:00","payload":{"action":"ended his term as","action_category":"role_change","departure_tone":"routine","effective_date":"2022-08-01","interim":true,"role":"Interim Chief Executive Officer","role_category":"ceo","successor_name":"Alexandra MacLean, M.D.","successor_named":true},"claim":"David Jin changed role as Interim Chief Executive Officer at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"With the appointment of Dr. MacLean as the new Chief Executive Officer, Mr. David Jin will end his term as interim Chief Executive Officer and will continue his responsibilities as Interim Chief Financial Officer and Chief Operating Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-085661","anchor_url":"https://secwatch.observer/filing/0001104659-22-085661#claim-2998da2eae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/0001104659-22-085661-index.htm"},{"fact_type":"executive_change","fact_key":"c7f8d7aec1","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-08-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-08-01","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Alexandra MacLean, M.D. was appointed as Chief Executive Officer at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"On August 1, 2022, the Board of Directors of Avenue Therapeutics, Inc. (the “ Company ”) appointed Alexandra MacLean, M.D., to serve as the Company’s Chief Executive Officer, with immediate effect.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-085661","anchor_url":"https://secwatch.observer/filing/0001104659-22-085661#claim-c7f8d7aec1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/0001104659-22-085661-index.htm"},{"fact_type":"executive_change","fact_key":"e5d6404320","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-05-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-05-16","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Faith L. Charles was appointed as director at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"On May 16, 2022, the Board appointed Faith L. Charles as a director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-061412","anchor_url":"https://secwatch.observer/filing/0001104659-22-061412#claim-e5d6404320","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922061412/0001104659-22-061412-index.htm"},{"fact_type":"executive_change","fact_key":"207fe89ec2","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-05-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-05-11","interim":true,"role":"Interim Principal Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"David Jin was appointed as Interim Principal Financial Officer at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"On May 11, 2022, Avenue Therapeutics, Inc. (the “Company”) appointed David Jin as the Company’s Interim Principal Financial Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-22-060416","anchor_url":"https://secwatch.observer/filing/0001104659-22-060416#claim-207fe89ec2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922060416/0001104659-22-060416-index.htm"},{"fact_type":"executive_change","fact_key":"4d08f426d4","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-03-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2022-03-31","interim":true,"role":"interim principal executive officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"David Jin was appointed as interim principal executive officer at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"David Jin, who was previously serving as the Company’s Chief Operating Officer, will begin acting as the Company’s interim principal executive officer as of March 31, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-040209","anchor_url":"https://secwatch.observer/filing/0001104659-22-040209#claim-4d08f426d4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/0001104659-22-040209-index.htm"},{"fact_type":"executive_change","fact_key":"c0a6cf6426","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-03-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-03-31","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"David Jin","successor_named":true},"claim":"Lucy Lu resigned as President and Chief Executive Officer at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"Lucy Lu, M.D. notified Avenue Therapeutics, Inc. (the “Company”) that she was resigning from her role as the Company’s President and Chief Executive Officer, and from her position as a member of the Company’s Board of Directors, effective in each case as of March 31, 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-040209","anchor_url":"https://secwatch.observer/filing/0001104659-22-040209#claim-c0a6cf6426","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/0001104659-22-040209-index.htm"},{"fact_type":"executive_change","fact_key":"56ee19615a","cik":1644963,"ticker":"ATXI","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-01-07T23:59:59+00:00","payload":{"action":"resigning","action_category":"departure","departure_tone":"routine","effective_date":"2022-01-14","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Lucy Lu","successor_named":true},"claim":"Joseph Vazzano departed as Chief Financial Officer at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"Mr. Joseph Vazzano notified Avenue Therapeutics, Inc. (the “Company”) that he was resigning from his role as the Company’s Chief Financial Officer, effective January 14, 2022, to pursue other opportunities.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-002269","anchor_url":"https://secwatch.observer/filing/0001104659-22-002269#claim-56ee19615a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922002269/0001104659-22-002269-index.htm"}]}